Thermo Fisher Scientific (TMO) is buying the Dutch diagnostics company Qiagen (QGEN) in an $11.5 billion deal that expands the laboratory equipment maker’s ability to detect infectious diseases, including the new coronavirus.

Qiagen announced last week that it had shipped a newly developed test kit to detect the virus that causes Covid-19 to four hospitals in China. The company says the kit can distinguish the novel coronavirus from 21 pathogens that cause serious respiratory disease and delivers results in about an hour with little effort by lab technicians. Qiagen was also shipping the kits to Europe, Southeast Asia, and the Middle East.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy